The Relevance of New Alzheimer Guidelines for Clinical Practice
The proposed new diagnostic categories and guidelines for Alzheimer's disease include not only dementia, but also the preclinical and mild cognitive impairment (MCI) phases of AD.
What are the new criteria for each stage of Alzheimer Disease (AD) and how are they relevant for clinical practice?
Here, in the second of his 2 podcasts, Dr Christopher van Dyck discusses the proposed new diagnostic categories and guidelines for AD (for Part 1, please click here). These categories include not only AD dementia, but also the preclinical and mild cognitive impairment (MCI) phases of AD. They also incorporate biomarkers (eg, amyloid PET imaging and CSF proteomics) of the underlying pathophysiological processes.
Dr van Dyck is Professor of Psychiatry, Neurology, and Neurobiology at Yale School of Medicine and Director of the Alzheimer’s Disease Research Unit at Yale in New Haven, Connecticut.
Further reading: New Diagnostic Criteria and Guidelines for Alzheimer's Disease.
